Upsher-Smith Completes Acquisition Of Dr Reddy’s Two Migraine Treatments

Upsher-Smith strategically expands and diversifies its portfolio by acquiring Dr Reddy’s two treatments of acute migraine in adults.

Migraine
Upsher-Smith adds a sumatriptan injection and sumatriptan nasal spray to its migraine portfolio • Source: Shutterstock

Upsher-Smith has announced that it has completed the acquisition of two Dr. Reddy's treatments of acute migraine for adults. This strategic acquisition of 3mg Zembrace Symtouch (sumatriptan injection) and 10mg Tosymra (sumatriptan nasal spray) is expected to expand and diversify Upsher-Smith’s portfolio.

Confirming the completion, Rusty Field, president and CEO of Upsher-Smith, stated that "more than 36 million Americans suffer from migraines, and Upsher-Smith is proud to be diversifying the portfolio with two products that can bring

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Generics Bulletin